세계 보톡스 시장 : 제품 유형별, 성별별, 연령층별, 용도별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Botox Market is accounted for $7.26 billion in 2023 and is expected to reach $17.63 billion by 2030 growing at a CAGR of 13.5% during the forecast period. A neurotoxic protein generated from the bacteria Clostridium botulinum is known as botox or botulinum toxin. It is used both medically and cosmetically to temporarily paralyze or relax muscles. It is also used to treat medical diseases such as hyperhidrosis, chronic headaches, muscle spasms, and movement abnormalities. Botox is administered by qualified medical personnel to prevent negative consequences, careful administration is crucial.

According to the America Society of Plastic Surgeon report, nearly 13% dip were observed in botulinum toxin procedures in 2020.

Market Dynamics:

Driver:

Rising demand in Botox injections

Botox injections have numerous other benefits, primarily enhancing physical appearance. For instance, Botox injections are frequently used to help people with temporomandibular joint (TMJ) or other types of muscle pain relax their muscles. Additionally, chronic health issues, including migraines, are treated with botox injections, it can reduce the excessive use of the muscles by blocking the activity of the muscles' nerves. Hence, botox injections can help those who experience excessive underarm sweating, urinary tract disorders, or an overactive bladder.

Restraint:

High Costs

For many people, the high expense of (botulinum toxin) Botox, might be a substantial barrier. Access to the treatment may be hampered by the cost, especially for those without sufficient financial means or health insurance. Furthermore, this financial barrier may hinder people from taking advantage of the toxin's medicinal or aesthetic effects, which may lower their quality of life or lower their self-esteem. Thus, the cost burden is made higher by the ongoing nature of botox treatments, which often call for several sessions over time.

Opportunity:

Increase in demand for non-invasive surgeries

People over the age of 40 tend to focus on their physical appearance and want to look young. Thus, it is projected that increasing female attention to aesthetic traits, particularly in developed nations, will accelerate the expansion of the demand for non-invasive surgeries. Additionally, botulinum toxin is utilized to treat a variety of aging-related problems, including crow's feet, glabellar lines, forehead lines, and others. People over 40 are therefore more likely to experience these indicators of aging. Therefore, botulinum toxin operations are becoming increasingly popular among people between the ages of 40 and 54, which are boosting market growth.

Threat:

Side Effects

Botox procedures are well regarded for having fewer risks and few side effects that typically go away within 24-48 hours. Moreover, some people could experience adverse effects that can continue for weeks. Examples of these include nausea, droopy eyes, a stiff neck, headaches, and more. Therefore, allergic reactions have often occurred; as a result, individuals taking antibiotics should take extra care before receiving botox therapy.

COVID-19 Impact

The limitations and lockdown measures put in place to stop the virus's spread led to the temporary closure of numerous dermatological and beauty clinics, which restricted access to botox treatments. Botox injection demand decreased as a result of non-essential medical procedures, such as aesthetic procedures, being delayed or stopped. Additionally, the economic crisis brought on by the epidemic has caused people to face financial difficulties, which have pushed them to be more careful about spending money on elective cosmetic surgeries. Therefore, in overall, the COVID-19 pandemic has drastically impacted the market for Botox, leading to a decline in demand and sales for these procedures.

The dermatology clinics segment is expected to be the largest during the forecast period

The dermatology clinics segment is estimated to hold the largest share. Botulinum toxin is frequently administered in dermatology workplaces, especially when used cosmetically. Additionally, these clinics specialize in the diagnosis and treatment of various skin diseases and provide botulinum toxin injections, a well-liked non-surgical method for eradicating wrinkles and small lines on the face. Dermatologists have the skills to evaluate patients' needs, choose the right dosage, and properly administer injections because they are licensed medical professionals. Furthermore, a controlled and hygienic atmosphere is offered by dermatology clinics, which frequently draw clients looking for cosmetic improvements.

The therapeutics segment is expected to have the highest CAGR during the forecast period

The therapeutics segment is anticipated to have highest CAGR during the forecast period, due to a variety of therapeutic and preventive treatments, including those for persistent migraines, overactive bladders, and hyperhidrosis, are carried out using botox procedures. Additionally, enhanced knowledge of the many mechanisms of action and molar behaviour of botulinum toxin has expanded its therapeutic potential. Hyperhidrosis and recurrent headaches are only two of the many disorders that can be treated with botox. Therefore, these aspects drive the market's growth.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to the rising disposable income, technological advancements in aesthetic botox procedures, and state-of-the-art facilities for surgery and treatment. Additionally, contributing to revenue growth in the area is the rising demand for cosmetic procedures, quick approvals, and verification of various botox treatments.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period, owing to the increased investment in R&D projects to launch new products is in the European region. For instance, according to the International Society of Aesthetic Plastic Surgery (ISAPS) (2021), 208,764 nonsurgical cosmetic procedures, including 75,348 botulinum toxin treatments, were performed in Spain. Additionally, the UK botulinum toxin market had the quickest rate of growth in the European region, while the German botulinum toxin market held the greatest market share.

Key players in the market:

Some of the key players in the Botox Market include: WorldMeds LLC., Syneron Candela, Solta Medical, AbbVie, Allergan Inc., Eisai Co., Ltd., Evolus, Inc.,Galderma S.A., Hugel, Inc, Ipsen Group, Lanzhou Institute of Biological Products Co. Ltd., Lumenis, Medy Tox Inc., Merz Pharma., Pfizer Inc., Revance Therapeutics Inc. and Solta Medical.

Key Developments:

In October 2022, Galderma and National Breast Cancer Foundation Inc. (NBCF) kept on their collaboration. Breast cancer survivors who had Restylane, Dysport (abobotulinumtoxinA), and/or Sculptra during Breast Cancer Awareness Month were profiled in a promotion on Galderma's social media channels.

In August 2022, the collaboration between Medytox and Bloomage Biotechnology has ended. According to Bloomage Biotechnology, since the joint venture agreement was signed, Medytox has never offered goods made by Medybloom China BTX for sale.

In July 2022, Fastox Pharma debuted the long-lasting botulinum toxin, known as LAST technology, during the "Toxins 2022 International Conference." Fastox discovered that the commencement of action of botulinum toxin type A (BoNT/A) should be accelerated by the addition of fast-acting myorelaxant drugs.

Product Types Covered:

• Botulinum Toxin B
• Botulinum Toxin A
• Other Product Types

Genders Covered:

• Male
• Female

Age Groups Covered:

• 13-19
• 20-29
• 30-39
• 40-54
• 55 and above

Applications Covered:

• Therapeutics
• Aesthetics
• Other Applications

End Users Covered:

• Spas and Cosmetic Centers
• Hospitals
• Dermatology Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Botox Market, By Product Type

• 5.1 Introduction
• 5.2 Botulinum Toxin B
• 5.3 Botulinum Toxin A
  • 5.3.1 Dysport
  • 5.3.2 Botox
  • 5.3.3 Xeomin
• 5.4 Other Product Types

6 Global Botox Market, By Gender

• 6.1 Introduction
• 6.2 Male
• 6.3 Female

7 Global Botox Market, By Age Group

• 7.1 Introduction
• 7.2 13-19
• 7.3 20-29
• 7.4 30-39
• 7.5 40-54
• 7.6 55 and above

8 Global Botox Market, By Application

• 8.1 Introduction
• 8.2 Therapeutics
  • 8.2.1 Overactive Bladder
  • 8.2.2 Chronic Migraine
  • 8.2.3 Spasticity
  • 8.2.4 Cervical Dystonia
  • 8.2.5 Other Therapeutics
• 8.3 Aesthetics
  • 8.3.1 Glabellar Lines
  • 8.3.2 Crow's Feet
  • 8.3.3 Forehead Lines
  • 8.3.4 Other Aesthetics
• 8.4 Other Applications

9 Global Botox Market, By End User

• 9.1 Introduction
• 9.2 Spas and Cosmetic Centers
• 9.3 Hospitals
• 9.4 Dermatology Clinics
• 9.5 Other End Users

10 Global Botox Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 WorldMeds LLC.
• 12.2 Syneron Candela
• 12.3 Solta Medical.
• 12.4 AbbVie
• 12.5 Allergan Inc.
• 12.6 Eisai Co., Ltd.
• 12.7 Evolus, Inc.
• 12.8 Galderma S.A.
• 12.9 Hugel, Inc
• 12.10 Ipsen Group
• 12.11 Lanzhou Institute of Biological Products Co. Ltd.
• 12.12 Lumenis
• 12.13 Medy Tox Inc.
• 12.14 Merz Pharma.
• 12.15 Pfizer Inc.
• 12.16 Revance Therapeutics Inc.
• 12.17 Solta Medical.